JP MORGAN/CALL/ELI LILLY & CO/1270/0.01/16.01.26 | Real-time Bid/Ask 10:31:15 23/05/2024 BST | ||
| 0.48 EUR / 0.51 EUR | +7.61% |
|
| Current month | +43.75% | ||
| 1 month | +48.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 0.46 | +17.95% |
| 21/05/24 | 0.39 | +5.41% |
| 20/05/24 | 0.37 | -2.63% |
| 17/05/24 | 0.38 | -7.32% |
| 16/05/24 | 0.41 | +17.14% |
Delayed Quote Börse Stuttgart
Last update May 22, 2024 at 11:23 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK6YC3 |
| ISIN | DE000JK6YC31 |
| Date issued | 04/04/2024 |
| Strike | 1,270 $ |
| Maturity | 16/01/2026 (604 Days) |
| Parity | 100 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.46 € |
|---|---|
| Lowest since issue | 0.29 € |
| Spread | 0.03 € |
| Spread % | 5.88% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.4
USD
Spread / Average Target
+5.92%
- Stock Market
- Warrants
- Warrant
